Companies Dominating the Cerebral Infarction Drugs Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Amneal Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- Edwards Lifesciences Corporation
- Daiichi Sankyo Company, Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of cerebral infarction drugs is assessed at USD 8.64 billion.
The cerebral infarction drugs market size was valued at USD 7.61 billion in 2024 and is expected to reach USD 21.2 billion by 2037, expanding at around 8.2% CAGR during the forecast period i.e., between 2025-2037. Worldwide growing prevalence of sedentary lifestyle, rising cases of arterial embolism, and rising ratio of clinical trials and their positive outcomes will boost the market growth.
North America industry is poised to hold largest revenue share of 50% by 2037, propelled by increasing frequency of cerebrovascular disease amongst several people, driven by sedentary lifestyle of individuals.
The major players in the market are Amgen Inc., Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Edwards Lifesciences Corporation, Daiichi Sankyo Company, Limited
